Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline Review, H2 2016’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease)

The report reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ankylosing Spondylitis (Bekhterev's Disease) therapeutics and enlists all their major and minor projects

The report assesses Ankylosing Spondylitis (Bekhterev's Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Alteogen Inc.

Amgen Inc.

BIOCAD

Biocon Limited

Bionovis SA

Brickell Biotech, Inc.

Celgene Corporation

Coherus BioSciences, Inc.

Genor BioPharma Co Ltd

Innovent Biologics, Inc.

Johnson & Johnson

Momenta Pharmaceuticals, Inc.

Mycenax Biotech Inc.

NeuClone Pty Ltd

Novartis AG

Oncobiologics, Inc.

Panacea Biotec Limited

Protalix BioTherapeutics, Inc.

Reliance Life Sciences Pvt. Ltd.

Sandoz International GmbH

Shanghai Pharmaceutical Co., Ltd.

Therapeutic Proteins International, LLC

Vitae Pharmaceuticals, Inc.

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Ankylosing Spondylitis (Bekhterev's Disease) Overview 8

Therapeutics Development 9

Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview 9

Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies 10

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies 16

Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 19

AbbVie Inc 19

Alteogen Inc. 20

Amgen Inc. 21

BIOCAD 22

Biocon Limited 23

Bionovis SA 24

Brickell Biotech, Inc. 25

Celgene Corporation 26

Coherus BioSciences, Inc. 27

Genor BioPharma Co Ltd 28

Innovent Biologics, Inc. 29

Johnson & Johnson 30

Momenta Pharmaceuticals, Inc. 31

Mycenax Biotech Inc. 32

NeuClone Pty Ltd 33

Novartis AG 34

Oncobiologics, Inc. 35

Panacea Biotec Limited 36

Protalix BioTherapeutics, Inc. 37

Reliance Life Sciences Pvt. Ltd. 38

Sandoz International GmbH 39

Shanghai Pharmaceutical Co., Ltd. 40

Therapeutic Proteins International, LLC 41

Vitae Pharmaceuticals, Inc. 42

Xbrane Biopharma AB 43

Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 44

Assessment by Monotherapy Products 44

Assessment by Target 45

Assessment by Mechanism of Action 47

Assessment by Route of Administration 49

Assessment by Molecule Type 51

Drug Profiles 53

adalimumab biosimilar - Drug Profile 53

adalimumab biosimilar - Drug Profile 55

adalimumab biosimilar - Drug Profile 56

adalimumab biosimilar - Drug Profile 57

adalimumab biosimilar - Drug Profile 58

adalimumab biosimilar - Drug Profile 59

adalimumab biosimilar - Drug Profile 60

adalimumab biosimilar - Drug Profile 62

adalimumab biosimilar - Drug Profile 64

adalimumab biosimilar - Drug Profile 65

adalimumab biosimilar - Drug Profile 66

adalimumab biosimilar - Drug Profile 67

adalimumab biosimilar - Drug Profile 68

adalimumab biosimilar - Drug Profile 69

apremilast - Drug Profile 70

BBI-6000 - Drug Profile 81

certolizumab pegol biosimilar - Drug Profile 83

DNX-114 - Drug Profile 84

DNX-514 - Drug Profile 85

etanercept biosimilar - Drug Profile 86

etanercept biosimilar - Drug Profile 87

etanercept biosimilar - Drug Profile 89

etanercept biosimilar - Drug Profile 90

etanercept biosimilar - Drug Profile 91

etanercept biosimilar - Drug Profile 92

etanercept biosimilar - Drug Profile 93

etanercept biosimilar - Drug Profile 96

etanercept biosimilar - Drug Profile 97

golimumab - Drug Profile 99

golimumab biosimilar - Drug Profile 107

golimumab biosimilar - Drug Profile 108

infliximab biosimilar - Drug Profile 109

infliximab biosimilar - Drug Profile 110

infliximab biosimilar - Drug Profile 111

infliximab biosimilar - Drug Profile 114

infliximab biosimilar - Drug Profile 115

infliximab biosimilar - Drug Profile 118

infliximab biosimilar - Drug Profile 119

infliximab biosimilar - Drug Profile 120

INV-17 - Drug Profile 121

risankizumab - Drug Profile 122

secukinumab - Drug Profile 125

thalidomide - Drug Profile 138

upadacitinib tartrate - Drug Profile 139

VTP-43742 - Drug Profile 141

Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 143

Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 145

Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 146

Featured News & Press Releases 146

Appendix 159

Methodology 159

Coverage 159

Secondary Research 159

Primary Research 159

Expert Panel Validation 159

Contact Us 159

Disclaimer 160

List of Tables

List of Tables

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Development by Companies, H2 2016 (Contd..2) 21

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by AbbVie Inc, H2 2016 22

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Alteogen Inc., H2 2016 23

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Amgen Inc., H2 2016 24

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by BIOCAD, H2 2016 25

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Biocon Limited, H2 2016 26

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Bionovis SA, H2 2016 27

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Brickell Biotech, Inc., H2 2016 28

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Celgene Corporation, H2 2016 29

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Coherus BioSciences, Inc., H2 2016 30

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Genor BioPharma Co Ltd, H2 2016 31

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Innovent Biologics, Inc., H2 2016 32

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Johnson & Johnson, H2 2016 33

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 34

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Mycenax Biotech Inc., H2 2016 35

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by NeuClone Pty Ltd, H2 2016 36

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Novartis AG, H2 2016 37

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Oncobiologics, Inc., H2 2016 38

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Panacea Biotec Limited, H2 2016 39

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Protalix BioTherapeutics, Inc., H2 2016 40

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016 41

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Sandoz International GmbH, H2 2016 42

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Shanghai Pharmaceutical Co., Ltd., H2 2016 43

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Therapeutic Proteins International, LLC, H2 2016 44

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 45

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Xbrane Biopharma AB, H2 2016 46

Assessment by Monotherapy Products, H2 2016 47

Number of Products by Stage and Target, H2 2016 49

Number of Products by Stage and Mechanism of Action, H2 2016 51

Number of Products by Stage and Route of Administration, H2 2016 53

Number of Products by Stage and Molecule Type, H2 2016 55

Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects, H2 2016 146

Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects (Contd..1), H2 2016 147

Ankylosing Spondylitis (Bekhterev's Disease) – Discontinued Products, H2 2016 148

List of Figures

List of Figures

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 47

Number of Products by Targets, H2 2016 48

Number of Products by Stage and Targets, H2 2016 48

Number of Products by Mechanism of Actions, H2 2016 50

Number of Products by Stage and Mechanism of Actions, H2 2016 50

Number of Products by Routes of Administration, H2 2016 52

Number of Products by Stage and Routes of Administration, H2 2016 52

Number of Products by Molecule Types, H2 2016 54

Number of Products by Stage and Molecule Types, H2 2016 54

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports